| 초록 |
Papillary renal cell carcinoma (pRCC) is the second most common subtype of renal cell carcinoma (RCC), with limited molecular characterization and prognostic biomarkers. Identifying key molecular signatures is crucial for understanding disease progression and improving patient outcomes. This study aimed to explore differentially expressed genes (DEGs) and prognostic factors in pRCC using bioinformatics approaches. Gene expression data were retrieved from Gene Expression Omnibus (GEO), the publicly available dataset, with accession number GSE15641. DEGs were identified using GEO2R, followed by pathway enrichment analysis using ShinyGO. Protein-protein interaction (PPI) networks were constructed with STRING, and survival analysis was performed using GEPIA2. A total of 565 DEGs were identified, with 402 upregulated and 163 downregulated genes. Pathway enrichment analysis highlighted the PPAR signaling pathway (FDR = 0.0223) as a key molecular signature, involving genes such as FABP1, GK, HMGCS2, APOC3, LPL, PCK1, and ADIPOQ. Survival analysis using GEPIA2 demonstrated that LPL expression was significantly correlated with patient survival (p = 0.0079), suggesting its potential as a prognostic biomarker. Other pathways enriched included PI3K-Akt, MAPK, and metabolic pathways, further supporting their roles in pRCC progression. In conclusion, this study identifies the PPAR signaling pathway as a critical molecular signature in pRCC and suggests LPL as a potential prognostic biomarker. These findings provide valuable insights into the molecular mechanisms of pRCC and may guide future therapeutic strategies. Further validation in clinical settings is required to confirm their prognostic and therapeutic potential. |